Preferred Label : KRAS G12C Inhibitor YL-15293;
NCIt definition : An orally bioavailable inhibitor of the oncogenic KRAS substitution mutation, G12C,
with potential antineoplastic activity. Upon oral administration, KRAS G12C inhibitor
YL-15293 selectively targets, binds to and inhibits the activity of the KRAS G12C
mutant, thereby inhibiting KRAS G12C mutant-dependent signaling. KRAS, a member of
the RAS family of oncogenes, serves an important role in cell signaling, division
and differentiation. Mutations of KRAS may induce constitutive signal transduction
leading to tumor cell growth, proliferation, invasion, and metastasis.;
Molecule name : YL-15293; YL 15293;
NCI Metathesaurus CUI : CL1773809;
Origin ID : C185398;
UMLS CUI : C5666981;
Semantic type(s)
concept_is_in_subset
has_target